Neha Agrawal

Neha Agrawal

Auto-generated profile, based on publicly available information

Neha Agrawal

Complete HEOR Solutions, North Wales, PA, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2022 in Current Medical Research and Opinion
Verified
Journal Article
Open access
KBKatharine Batt
Katharine Batt
BSBob G. Schultz
Bob G. Schultz
JCJorge Caicedo
Jorge Caicedo
CHChristopher S. Hollenbeak
Christopher S. Hollenbeak
NANeha Agrawal
Neha Agrawal
MBMichael Bullano
Michael Bullano
Factor VIII (FVIII) replacement and emicizumab have demonstrated efficacy for prevention of bleeds among patients with hemophilia A (PwHA) compared to on-demand (OD) use. Evidence investigating cli...

1 October 2020 in Pediatric Health, Medicine and Therapeutics
Verified
Journal Article
Open access
PDF file
XYXiaoqin Yang
Xiaoqin Yang
KDKaushal Desai
Kaushal Desai
NANeha Agrawal
Neha Agrawal
KMKirti Mirchandani
Kirti Mirchandani
SCSagnik Chatterjee
Sagnik Chatterjee
SSShuvayu Sen
Shuvayu Sen
Background: Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic condition which predisposes individuals to tumors of the nervous system, skin, bones, and eyes. Plexiform neurofibromas (PNs) occur in 20– 50% of NF1 cases, causing multiple morbidities and conferring a risk of malignancy. NF1 with PN is poorly characterized in the literature with regard to treatment patterns, healthcare resource utilization, and costs in the real world. Methods: This was a retrospective analysis of data from a commercial claims database in the US between October 2014 and March 2018. Persons with at least 1 diagnostic code for both NF1 and PN, aged ≤ 18 years on the index date, and continuously enrolled for ≥ 12 months before the index date were included. The index date was defined as the date of the first diagnosis of NF1 or PN during the study period, whichever occurred later. Healthcare resource utilization during follow-up included outpatient, inpatient, emergency room (ER), and pharmacy encounters; corresponding costs were calculated as the mean per patient per year (PPPY) in 2018 US dollars. Treatments were classified as PN surgery, pain medication, chemotherapy, radiotherapy, and targeted therapies. All analyses were descriptive. Results: A total of 301 patients were included. In the follow-up period, nearly all patients (99.7%) had outpatient visits, while 81.1% had pharmacy visits, 25.2% had ER visits, and 13.0% had inpatient visits. Mean ± SD [median] total healthcare costs PPPY were $38,292 ± $80,556 [$16,037]. During follow-up, 44.2% of patients used pain medications, 23.9% received chemotherapy, 5.0% underwent surgery for PN, 1.3% received radiotherapy, and 1.0% received targeted therapies. Conclusion: Commercially insured pediatric patients diagnosed with NF1 and PN were treated primarily with supportive care, highlighting a substantial unmet need in the United States.

10 January 2020 in International Journal of Current Microbiology and Applied Sciences
Verified
Journal Article
Open access
NANeha Agrawal
Neha Agrawal
PUPriyanka Upadhyay
Priyanka Upadhyay
STSantosh B. Tigadi
Santosh B. Tigadi
International Journal of Current Microbiology and Applied Sciences ISSN:2319-7692(Print), ISSN:2319-7706(Online) is a multidisciplinary peer-reviewed journal with reputable academics and experts as members of its Editorial Board. The Current Microbiology aims to publish all the latest and outstanding research articles. Review and letters in all areas of major importance to techniques of microbiology and applied research with publishes high quality of review and research articles on novel aspects of Microbiology including Environmental, Food, Agricultural, Medical, Pharmaceutical, Veterinary, Soil, Water and Biodeterioration.

17 April 2023 in Journal of Medical Economics
Verified
Journal Article
Open access
MEMiguel Escobar
Miguel Escobar
NANeha Agrawal
Neha Agrawal
SCSagnik Chatterjee
Sagnik Chatterjee
SBSwastik Bhattacharya
Swastik Bhattacharya
JCJorge Caicedo
Jorge Caicedo
BSBob G. Schultz
Bob G. Schultz
Factor VIII (FVIII) replacement and emicizumab are effective at preventing bleeds in patients with hemophilia A (HA). Though benefits of emicizumab among inhibitor patients with HA (PwHA) are well ...